Please wait a minute...
Reviews in Cardiovascular Medicine  2020, Vol. 21 Issue (2): 191-203     DOI: 10.31083/j.rcm.2020.02.17
Special Issue: Cardiovascular disorders in chronic kidney disease
Review Previous articles | Next articles
High-sensitivity troponin in chronic kidney disease: Considerations in myocardial infarction and beyond
Anthony (Ming-yu) Chuang1, 2, *(), Mau T Nguyen3, Woon-Man Kung4, Sam Lehman1, 2, Derek P Chew1, 2
1School of Medicine, Flinders University of South Australia, Adelaide 5042, Australia
2Department of Cardiovascular Medicine, Southern Adelaide Local Health Network, Adelaide 5042, Australia
3Vascular Research Centre, Lifelong Health Theme, South Australian Health and Medical Research Institute (SAHMRI), Adelaide 5000, Australia
4Department of Exercise and Health Promotion, College of Education, Chinese Culture University, Taipei 11114, Taiwan
Download:  PDF(1018KB)  ( 1868 ) Full text   ( 125 )
Export:  BibTeX | EndNote (RIS)      
Acute myocardial infarction (MI) represents one of the most common hospital encounters, with significant short-term and long-term morbidity and mortality, and frequently occurs in patients with chronic kidney disease (CKD). Cardiac troponin is an exquisitely sensitive biomarker for myocardial injury and plays an essential role in the diagnosis, risk-stratification, and management of MI. In 2017, the United States Food and Drug Administration approved Roche Diagnostics' 5th generation high-sensitivity cardiac troponin (hs-cTn) for clinical use. Whilst the improved analytical sensitivity of these new high-sensitivity troponin assays facilitate early diagnosis of MI, it also frequently identifies troponin elevations above the conventional reference threshold in the context of non-coronary conditions such as renal dysfunction, and can represent a major diagnostic challenge to clinicians. Furthermore, the optimal management strategy of patients with troponin elevation and high comorbidity burden, a common issue in patients with CKD, remains undefined. In recent years, there has been substantial research and progress undertaken in this rapidly evolving area. In this review, we aim to provide clinicians with an overview of hs-cTn in the setting of CKD as well as an update on its application and the particular considerations involved in the management of myocardial infarction, stable coronary artery disease and myocardial injury in this high risk population.
Key words:  High-sensitivity troponin      chronic kidney disease      coronary artery disease      myocardial injury      dialysis     
Submitted:  04 February 2020      Revised:  16 April 2020      Accepted:  20 April 2020      Published:  30 June 2020     
*Corresponding Author(s):  Anthony (Ming-yu) Chuang     E-mail:

Cite this article: 

Anthony (Ming-yu) Chuang, Mau T Nguyen, Woon-Man Kung, Sam Lehman, Derek P Chew. High-sensitivity troponin in chronic kidney disease: Considerations in myocardial infarction and beyond. Reviews in Cardiovascular Medicine, 2020, 21(2): 191-203.

URL:     OR

[1] Hai-Fu Zhang, Qin-Xia Zhang, Yuan-Yuan Zhang, Dong Yang, Zhao Xu, Qi-Bin Jiao, Xing-Wei Zhang. Efficacy and safety of left atrial appendage occlusion in atrial fibrillation patients with chronic kidney disease: a systematic review and meta-analysis[J]. Reviews in Cardiovascular Medicine, 2020, 21(3): 443-451.
[2] Meer Fakhry, Mandeep S. Sidhu, Sripal Bangalore, Roy O. Mathew. Accelerated and intensified calcific atherosclerosis and microvascular dysfunction in patients with chronic kidney disease[J]. Reviews in Cardiovascular Medicine, 2020, 21(2): 157-162.
[3] Zhanru Qi, Hongyan Zheng, Zhonghai Wei, Qing Dai, Jun Xie, Lian Wang, Jingmei Zhang, Jie Song. Short-term and long-term outcomes of bailout versus planned coronary rotational atherectomy[J]. Reviews in Cardiovascular Medicine, 2020, 21(2): 309-314.
[4] Megan S. Joseph, Maryse Palardy, Nicole M. Bhave. Management of heart failure in patients with end-stage kidney disease on maintenance dialysis: a practical guide[J]. Reviews in Cardiovascular Medicine, 2020, 21(1): 31-39.
[5] Yuhong Liu, Zhihuan Zeng, Xing Yu, Tudi Li, Yusi Yao, Rong Chen, Jianyi Zheng. Impact of lipoprotein(a) on long-term outcomes after percutaneous coronary intervention in patients with reduced low-density lipoprotein cholesterol[J]. Reviews in Cardiovascular Medicine, 2020, 21(1): 147-153.
[6] Michele Provenzano, Giuseppe Coppolino, Teresa Faga, Carlo Garofalo, Raffaele Serra, Michele Andreucci. Epidemiology of cardiovascular risk in chronic kidney disease patients: the real silent killer[J]. Reviews in Cardiovascular Medicine, 2019, 20(4): 209-220.
[7] Davide Bolignano, Anna Pisano, Graziella D’Arrigo. Pulmonary hypertension: a neglected risk condition in renal patients?[J]. Reviews in Cardiovascular Medicine, 2018, 19(4): 117-121.
[8] Sivakumar Sudhakaran, Teodoro Bottiglieri, Kristen M. Tecson, Aaron Y. Kluger, Peter A. McCullough. Alteration of lipid metabolism in chronic kidney disease, the role of novel antihyperlipidemic agents, and future directions[J]. Reviews in Cardiovascular Medicine, 2018, 19(3): 77-88.
[9] Peter A. McCullough, Aaron Y. Kluger, Kristen M. Tecson, Clay M. Barbin, Andy Y. Lee, Edgar V. Lerma, Zachary P. Rosol, Sivan L. Kluger, Janani Rangaswami. Inhibition of the Sodium–Proton Antiporter (Exchanger) is a Plausible Mechanism of Potential Benefit and Harm for Drugs Designed to Block Sodium Glucose Co-transporter 2[J]. Reviews in Cardiovascular Medicine, 2018, 19(2): 51-63.
[10] Christian O. Koelbl, Zoran S. Nedeljkovic, Alice K. Jacobs. Coronary Chronic Total Occlusion (CTO): A Review[J]. Reviews in Cardiovascular Medicine, 2018, 19(1): 33-39.
[11] Akanksha Agrawal, Deepanshu Jain, Eyob L. Feyssa, Aman M. Amanullah. Utility of Dobutamine Stress Echocardiography in Cardiac Risk Stratification of Patients Undergoing Orthotopic Liver Transplantation[J]. Reviews in Cardiovascular Medicine, 2017, 18(4): 146-154.
[12] Claudio Ronco, Federico Ronco, Peter A. McCullough. A Call to Action to Develop Integrated Curricula in Cardiorenal Medicine[J]. Reviews in Cardiovascular Medicine, 2017, 18(3): 93-99.
[13] Mehul A. Pragani, Karan P. Desai, Doralisa Morrone, Mandeep S. Sidhu, William E. Boden. The Role of Nitrates in the Management of Stable Ischemic Heart Disease: A Review of the Current Evidence and Guidelines[J]. Reviews in Cardiovascular Medicine, 2017, 18(1): 14-20.
[14] Sandeep K. Krishnan, Norman E. Lepor. Acute and Chronic Cardiovascular Effects of Hyperkalemia: New Insights Into Prevention and Clinical Management[J]. Reviews in Cardiovascular Medicine, 2016, 17(S1): 9-21.
[15] Raghunandan Muppidi, Laura Spranklin, William Scialla, Nauman Islam, Ronald Freudenberger, Robert Malacoff. Cardiotoxicity of Anticancer Therapies[J]. Reviews in Cardiovascular Medicine, 2015, 16(4): 225-234.
No Suggested Reading articles found!